Maya Eskandarani's questions to Mediwound Ltd (MDWD) leadership • Q2 2025
Question
In a follow-up, Maya Eskandarani of H.C. Wainwright & Co. asked about the risk of FDA inspection delays for the new facility and whether the BARDA RFP and DoD funding for a room-temperature stable NexoBrid formulation overlap.
Answer
CEO Ofer Gonen stated he does not foresee issues with the FDA inspection timeline, as it's expected in late 2026, and noted that revenue guidance is primarily dependent on the EMA approval, which faces no such delays. He confirmed that both BARDA and the DoD are interested in the room-temperature stable formulation, highlighting its dual military and civilian applications.